U.S. federal officials have announced the arrest of two senior executives of a Canadian healthcare company, accusing them of running a scheme to illegally import prescription drugs into the United States, according to court documents.
The indictment alleges that the officials coordinated the cross‑border movement of prescription medications without the required approvals, violating federal drug‑importation laws. Prosecutors say the operation was designed to bypass standard regulatory checks and supply the U.S. market with unapproved pharmaceuticals.
Court records filed in a federal district court detail the charges and outline the alleged methods used to conceal the shipments, including false labeling and the use of shell companies. The documents indicate that the investigation was conducted by multiple U.S. agencies, though specific agencies are not named in the filing.
Illegal importation of prescription drugs has drawn heightened scrutiny from U.S. regulators in recent years, as authorities seek to curb the flow of unverified medicines that may pose safety risks to patients. The case adds to a growing number of enforcement actions targeting cross‑border pharmaceutical networks.
<small>Source: CNBC — read the original story there.</small>